Changing the world,
one ‘tide’ at a time

Big vision statement, even bigger mission! Bachem, based in Switzerland, specialises in the development and manufacture of peptides and oligonucleotides for the pharmaceutical and biotech spaces worldwide. Peptides and oligonucleotides are two of the most interesting molecular platforms for making bioactive materials, important elements in the development of innovative medicines and advanced beauty products.

Bachem has been in the market since 1971, renown for their manufacturing of peptides, generics (active pharmaceutical ingredients) and cosmetics. They’ve recently begun to use their expertise and resources to manufacture oligonucleotides, which is the newest molecular platforms in genetic research, DNA sequencing, therapeutics, gene editing, DNA and RNA diagnostics, biotechnology and nanotechnology as well as pharmacokinetics and pharmacodynamics. Bachem are also intentional about their sustainability efforts—in line with our specialisation in ESG communication.

Bachem approached Bright8 for a cohesive strategy in elevating their 2023 mediaplanning to the next level, beyond mere 3rd party media buys. They were also looking for a smarter way of increasing global exposure for their oligonucleotides.

We know the market.
We know how to work the market.

Enter Bright8. One of our unique strengths is how well we know the markets for the varied clients we serve. Our experience and working knowledge of the pharmaceutical, biotech and life science industries at a global scale is second to none—Rain Man style! This enables us to not only understand the markets Bachem operates within, but how to manipulate the media landscape to suit our client’s goals at a uniquely Bright8 level.

If we do not know the market well enough, you’d better believe the depth of deep diving we undertake—we find it a priority to understand the stakeholder landscape in detail in order to best serve our client’s awareness and lead generation objectives.

We took the time to produce a complex media buying 2023 plan for Bachem across each of its five main business vertical pillars—general awareness of Bachem, peptides, generics, oligonucleotides and specialties (including cosmetics)—that incorporated multiple objectives and media streams. Our plan includes developing smart campaigns that hyper-target the audience via branding, reach, lead generation and engagement, using display banners, LinkedIn ads and third-party media buys with trade titles.

Super smart strategies

Our strategy through smart hyper-targeting allows us to better use the client’s budget on the most relevant audience segments, reducing wasted impressions and clicks. By honing in on individuals who are more likely to be interested in your client’s products or services, we optimise the advertising spend to achieve a better return on investment (ROI). Our digital campaigns through social media streams like LinkedIn allow us to target audience whilst at their professional environments. We carefully select third party channels for lead generation opportunities, including whitepapers and webinars to boost Bachem’s credibility and authority in the biotech and pharmaceutical industries.

As always, our strategy includes optimal contact frequency, specifying targeting options and phase of the sales funnel the potential customer is in; with as little waste as possible so that our client reaches the right people at the right time via the right medium.

And of course, our in-house studio produces digital display banners, animations and digital ads to accompany our strategy output.

Local, global, glocal… it’s all in our wheelhouse

Bright8 is borderless—we are as comfortable working for our local Dutch clients as we are for continents. Being an established biotech, Bachem’s target audiences are situated all across the world and that’s no problem for us. It is helpful that our team are from all over the world—and speak many languages amongst us!

Coway Logo

Bachem is a leading, innovation-driven company specialising in the development and manufacture of peptides and oligonucleotides, based in Switzerland, with clients in Europe, USA and Asia.